Minimal Residual Disease (MRD) ratio before and after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma

被引：0
|
作者：
Boncompagni, Riccardo [1 ]
Staderini, Michela [2 ]
Nozzoli, Chiara [1 ]
Antonioli, Elisabetta [2 ]
Caporale, Roberto [3 ]
Peruzzi, Benedetta [3 ]
Cutini, Ilaria [1 ]
Gozzini, Antonella [1 ]
Serena, Mariotti [1 ]
Guidi, Stefano [1 ]
Jance, Blerina [3 ]
Accogli, Barbara [2 ]
Francesco, Annunziato [3 ]
Bosi, Alberto [2 ]
Saccardi, Riccardo [1 ]
机构：
[1] AOU Careggi, Cell Therapy & Transfus Med Unit, Florence, Italy
[2] AOU Careggi, Hematol Unit, Florence, Italy
[3] AOU Careggi, Diagnost Ctr Cytometry & Immunotherapy, Florence, Italy
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
autologous stem cell transplant; Minimal residual disease; Progression-free survival;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FP-203
引用
收藏
页码：E172 / E172
页数：1
相关论文
共 50 条
  • [1] Deferring autologous stem cell transplantation for consolidation of minimal residual disease in multiple myeloma
    Braunstein, Marc
    Niesvizky, Ruben
    SEMINARS IN ONCOLOGY, 2016, 43 (06) : 709 - 711
  • [2] Multiple myeloma: Maintenance therapy after autologous stem cell transplantation, depending on minimal residual disease
    Solovyev, M. V.
    Mendeleeva, L. P.
    Pokrovskaya, O. S.
    Nareyko, M. V.
    Firsova, M. V.
    Galtseva, I. V.
    Davydova, Yu. O.
    Kapranov, N. M.
    Kuzmina, L. A.
    Gemdzhian, E. G.
    Savchenko, V. G.
    TERAPEVTICHESKII ARKHIV, 2017, 89 (07) : 25 - 31
  • [3] The Value of Minimal Residual Disease as a Progression-Free Survival Predictor After Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients
    Solovev, Maxim
    Mendeleeva, Larisa
    Firsova, Maiia
    Julhakyan, Hunan
    Galtseva, Irina
    Davydova, Julia
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S324 - S324
  • [4] Prognostic Significance of Minimal Residual Disease Testing by Multiparameter Flow Cytometry in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
    Mostafa, Nevine
    El-Salakawy, Walaa
    Abdelbary, Haitham
    Radwan, Rania
    Fathy, Rasha
    Abouelmagd, Yasmin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S300 - S300
  • [5] Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
    Maiolino, Angelo
    Da Costa, Elaine Sobral
    Orfao, Alberto
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [6] Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation
    Jacobs, Ryan W.
    Saliba, Rima M.
    Sasaki, Koji
    Farhan, Shatha
    Armas, Aristides
    Shah, Nina D.
    Bashir, Qaiser
    Qureshi, Sofia
    Rondon, Gabriela
    Hosing, Chitra
    Popat, Uday
    Parmar, Simrit
    Shah, Jatin J.
    Wang, Michael
    Weber, Donna M.
    Thomas, Sheeba K.
    Orlowski, Robert Z.
    Champlin, Richard E.
    Qazilbashi, Muzaffar H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (01) : 36 - 42
  • [7] The Level of Minimal Residual Disease in the Bone Marrow of Patients with Multiple Myeloma before High-Dose Therapy and Autologous Blood Stem Cell Transplantation Is an Independent Predictive Parameter
    Korthals, Mark
    Sehnke, Nina
    Kronenwett, Ralf
    Bruns, Ingmar
    Mau, Jochen
    Zohren, Fabian
    Haas, Rainer
    Kobbe, Guido
    Fenk, Roland
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (03) : 423 - 431
  • [8] Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation
    Pasvolsky, Oren
    Pasyar, Sarah
    Bassett, Roland L.
    Khan, Hina N.
    Tanner, Mark R.
    Bashir, Qaiser
    Srour, Samer
    Saini, Neeraj
    Lin, Paul
    Ramdial, Jeremy
    Nieto, Yago
    Lee, Hans C.
    Patel, Krina K.
    Kebriaei, Partow
    Thomas, Sheeba K.
    Weber, Donna M.
    Orlowski, Robert Z.
    Shpall, Elizabeth J.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    CANCER, 2024, 130 (09) : 1663 - 1672
  • [9] Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation
    Takamatsu, H.
    Takezako, N.
    Zheng, J.
    Moorhead, M.
    Carlton, V. E. H.
    Kong, K. A.
    Murata, R.
    Ito, S.
    Miyamoto, T.
    Yokoyama, K.
    Matsue, K.
    Sato, T.
    Kurokawa, T.
    Yagi, H.
    Terasaki, Y.
    Ohata, K.
    Matsumoto, M.
    Yoshida, T.
    Faham, M.
    Nakao, S.
    ANNALS OF ONCOLOGY, 2017, 28 (10) : 2503 - 2510
  • [10] Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation
    Jingyu Xu
    Wenqiang Yan
    Huishou Fan
    Jiahui Liu
    Lingna Li
    Chenxing Du
    Shuhui Deng
    Weiwei Sui
    Yan Xu
    Lugui Qiu
    Gang An
    Annals of Hematology, 2023, 102 : 3195 - 3204
12345